News
Eli Lilly Stock Soars on Oral Weight-Loss Drug Trial Results
Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.
Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.
Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...
A trial was conducted comparing weight loss medications Zepbound and Wegovy ... one other weight-related health ...
Hosted on MSN29d
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%needle-free alternative in the booming weight loss and diabetes market. Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage ...
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback